Bridgeway Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Bridgeway Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-7,350	Closed	-$107K	–	1567
2015 Q3	$107K	Hold	7,350	–	–	﹤0.01%	1390
2015 Q2	$143K	Hold	7,350	–	–	﹤0.01%	1401
2015 Q1	$133K	Buy	7,350 +2,370	+48%	+$53.3K	﹤0.01%	1384
2014 Q4	$118K	Buy	+4,980	New	+$115K	﹤0.01%	1375

Other funds holding CTIC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bridgeway Capital Management's CTIC Position: Q4 2015 in Review

Bridgeway Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2015, closing a stake of 7,350 shares — an estimated $107K sold.

Bridgeway Capital Management first reported a position in CTIC in Q4 2014 and held it in 4 quarters. The position peaked at $143K in Q2 2015. 94 funds tracked by Wall St. Rank hold CTIC as of Q4 2015.

Bridgeway Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2015 after selling out during the quarter.
Bridgeway Capital Management sold 7,350 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2015, an estimated $107K.
Bridgeway Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 4 quarters.
Bridgeway Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $143K in Q2 2015.
94 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2015.

Based on Bridgeway Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.